logo
Plus   Neg
Share
Email

Geron Stock Plunges After Johnson & Johnson Ends Collaboration Deal

Shares of Geron Corp. (GERN) plunged 62 percent in regular trading on Thursday after the biotech firm reported that Johnson & Johnson terminated a collaboration and license agreement with the company for experimental cancer drug imetelstat.

Geron said Janssen Biotech Inc., a subsidiary Johnson & Johnson, has terminated the 2014 Collaboration and License Agreement with the company.

Janssen, in a statement said, it made this decision as the result of a strategic portfolio evaluation and prioritization of assets within their portfolio.

Geron has regained the global rights to develop and commercialize imetelstat, a first-in-class telomerase inhibitor.

Under the groups' collaboration deal, Janssen held rights to develop to the drug in oncology, including haematologic myeloid malignancies.

"We are grateful for the collaboration with Janssen, who successfully managed two Phase 2 trials of imetelstat," said CEO John Scarlett. "We believe the clinical results from IMbark provide valuable insights into the potential future development of imetelstat for an underserved relapsed and refractory myelofibrosis patient population. We also believe the combined data of 38 patients from the initial and expansion cohorts for the target patient population from the Phase 2 portion of IMerge support further development of imetelstat, and we are therefore prioritizing the initiation of the Phase 3 portion of Imerge."

Transition of the imetelstat program to Geron is expected to occur over around 12 months with operational support from Janssen.

GERN closed Thursday's trading at $2.31, down $3.92 or 62.92%, on the Nasdaq.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration (FDA) has gone ahead with the approval of antiviral drug remdesivir as first treatment for COVID-19, notwithstanding last week's findings by the World Health Organization (WHO) that the drug is not effective for COVID-19 treatment. Thursday, Gilead Sciences announced that the FDA approved remdesivir, sold under the brand name Veklury. Integrated payments firm American Express Co. (AXP) reported Friday that net income for the third quarter declined to $1.1 billion or $1.30 per share from $1.8 billion or $2.08 per share in the prior-year quarter. Consolidated total revenues, net of interest expense, also decreased 20 percent to $8.8... The Federal Trade Commission or FTC has launched a new fraud reporting platform, using which, consumers can easily report fraud and all other consumer issues directly to the regulator. In a statement, the FTC said its new website, ReportFraud.ftc.gov, will provide a streamlined and user-friendly way to submit reports about scams, frauds, and bad business practices.
RELATED NEWS
Follow RTT